Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin- receptor blocker, on morbidity and mortality in chronic congestive heart failure

Journal of Cardiac Failure

Volumn 5, Issue 2, 1999, Pages 155-160

  Cohn, Jay N ^a   Tognoni, Gianni ^b   Glazer, Robert D ^c   Spormann, Dirk ^c   Hester, Allen ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiotensin receptor blockers; Heart failure; Mortality

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; ENALAPRIL; VALSARTAN;

ADULT; AGED; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL;

EID: 0032995724     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(99)90038-6     Document Type: Article

References (24)

1. Kannel WB, Belanger AJ: Epidemiology of heart failure. Am Heart J 1991;121:951-57
2. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. New Engl J Med 1987;316:1429-35
3. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
4. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10
5. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on Behalf of the SAVE Investigators: The effect of captopril on mortality and morbidity in patients with left ventricular dysfunction following myocardial infarction: Results of the Survival and Ventricular Enlargement (SAVE) trial. N Engl J Med 1992;327:669-77
6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8
7. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbæk J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) Study Group: A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;33:1670-6
8. Curtiss C, Cohn JN, Vrobel T, Franciosa JA: Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978;58:763-70
9. Aceto JF, Baker KM: [SAR'] Angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol 1990;258:H806-13
10. Weber KT, Janicki JS: Angiotensin and the remodeling of the myocardium. Brit J Clin Pharmacol 1989;28:141S-50S
11. Urata H, Healy B, Stewart RW, Bumpus FM, Hussain A: Antgiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-90
12. Balcells E, Meng QC, Johnson WH, Oparil S, Dell'Italia LJ: Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997;273:H1769-74
13. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN: Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043-8
14. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M: Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88: 1602-9
15. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E, for the Losartan Hemodynamic Study Group: Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995;91:691-7
16. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52
17. Rousseau MF, Konstam MA, Benedict CR, Donckier J, Galanti L, Melin J, Kinan D, Ahn S, Ketelslegers J-M, Pouleur H: Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994;73:488-93
18. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN for the V-HeFT Study Group: Augmented acute and chronic hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin-converting enzyme inhibitor therapy in patients with heart failure. Circulation (in press) 1999
19. McKelvie R, Yusuf S, Perjak D, Held P: Comparison of candesartan, enalapril and their combination in congestive heart failure: randomised evaluation of strategies for left ventricular dysfunction (RESOLVD pilot study). Eur Heart J 1998;19:133 (abstr, suppl)
20. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55
21. Cohn JN, Francis GS: Cardiac failure: a revised paradigm. J Card Fail 1995;1:261-6
22. Cohn JN, Goldstein S, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F III, DeMets DL, White BG for the Vesnarinone Trial Investigators: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339: 1810-6
23. Criscione L, Bradley W, Buhlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, de Gasparo M: Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995;13: 230-50
24. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group: Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87:VI40-8